Breaking News, Collaborations & Alliances

SunGen, Athenex Launch Busulfan Injection

Ownership transferred from Sandoz to the companies, with 2018 US Sales topping $33.6M according to IQVIA data

SunGen Pharma announced the launch of Busulfan Injection, the second product launch through their joint venture Peterson Athenex with Athenex Pharmaceuticals. The ownership of the approved US ANDA was transferred from Sandoz, a Novartis Division, to SunGen and Athenex.  The Busulfan Injection is distributed as a prefilled liquid vial with a strength of 6mg/ml in packs of 8. US Market Sales of Busulfan Injection were $33.6M for the year ending December 2018 according to IQVIA data.  Busulfan i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters